Financial reports
NT 10-Q
Notice of late quarterly filing
12 Aug 22
10-Q
2022 Q1
Quarterly report
23 May 22
NT 10-Q
Notice of late quarterly filing
16 May 22
10-K
2021 FY
Annual report
15 Apr 22
NT 10-K
Notice of late annual filing
30 Mar 22
10-Q
2021 Q3
Quarterly report
12 Nov 21
10-Q
2021 Q2
Quarterly report
6 Aug 21
10-Q
2021 Q1
Quarterly report
13 May 21
10-K
2020 FY
Annual report
30 Mar 21
10-Q
2020 Q3
Quarterly report
12 Nov 20
Current reports
8-K
Entry into a Material Definitive Agreement
24 Mar 22
8-K
Regulation FD Disclosure
28 Sep 21
8-K
Departure of Directors or Certain Officers
17 Mar 21
8-K
Entry into a Material Definitive Agreement
23 Feb 21
8-K
Neuropathix, Inc. Acquires Neuroprotective and Anticonvulsant Intellectual Property Estate
21 Dec 20
8-K
Neuropathix, Inc. Signs Binding Letter of Intent to Acquire Anticonvulsant – Neuroprotective Intellectual Property
19 Nov 20
8-K
Kannalife, Inc. Rebrands as Neuropathix, Inc.; Reveals New Name, Ticker Symbol, Updated Logo and Visual Identity
6 Nov 20
8-K
Entry into a Material Definitive Agreement
22 Sep 20
8-K
Entry into a Material Definitive Agreement
29 Jun 20
8-K
Entry into a Material Definitive Agreement
11 Jun 20
Registration and prospectus
POS AM
Prospectus update (post-effective amendment)
23 Jun 21
D
$1.21M in equity / options / securities to be acquired, sold $1.21M, 1 investor
23 Feb 21
S-1
IPO registration
22 Sep 20
D
$3M in debt / options / securities to be acquired, sold $100K, 1 investor
14 Jan 20
S-1/A
IPO registration (amended)
8 Aug 19
S-1/A
IPO registration (amended)
30 Jul 19
S-1/A
IPO registration (amended)
5 Jul 19
S-1/A
IPO registration (amended)
17 Jun 19
S-1/A
IPO registration (amended)
23 May 19
S-1/A
IPO registration (amended)
9 Apr 19
Proxies
No filings
Other
REVOKED
Registration or securities revoked
20 Oct 23
EFFECT
Notice of effectiveness
6 Jul 21
EFFECT
Notice of effectiveness
5 Oct 20
CORRESP
Correspondence with SEC
30 Sep 20
UPLOAD
Letter from SEC
29 Sep 20
CT ORDER
Confidential treatment order
14 Aug 19
EFFECT
Notice of effectiveness
13 Aug 19
CORRESP
Correspondence with SEC
8 Aug 19
UPLOAD
Letter from SEC
7 Aug 19
CORRESP
Correspondence with SEC
30 Jul 19